Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epacadostat with Cladribine and Cytarabine in R/R AML
NCT03491579Phase 1Withdrawn
- Sponsor
- Insel Gruppe
- Start
- Dec 2018
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of epacadostat in acute myeloid leukemia (AML), sponsored by Insel Gruppe. Primary endpoint: Maximum Tolerated Dose and Dose-Limiting Toxicities at 30 days. Planned start Dec 2018; status: withdrawn.
02
Drugs
epacadostat
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03491579.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03491579.